• Truist Financial sets a price target of $798 for Regeneron Pharmaceuticals (NASDAQ:REGN), indicating a potential increase.
• Regeneron's stock shows resilience with a 1.71% increase despite broader market volatility.
• The company's significant market capitalization of approximately $79.4 billion underscores its prominence in the biotech industry.

Regeneron Pharmaceuticals (NASDAQ:REGN) is a leading biotechnology company known for its innovative medicines. The company focuses on developing treatments for serious diseases, including eye diseases, cancer, and allergic conditions. Regeneron competes with other biotech giants like Amgen and Biogen. Recently, Truist Financial set a price target of $798 for Regeneron, suggesting a potential price increase of 4.11% from its current price of $766.50.

The stock market has been volatile, with significant swings following NVIDIA Corp's earnings report. Despite this, Regeneron's stock has shown resilience. Currently priced at $768.79, it reflects a 1.71% increase, or $12.89, from its previous value. The stock has fluctuated between $757 and $773.13 today, indicating investor interest and activity.

Regeneron's market capitalization stands at approximately $79.4 billion, highlighting its significant presence in the biotech industry. The stock's trading volume today is 156,611 shares on the NASDAQ exchange. This level of activity suggests that investors are closely watching Regeneron's performance amid the broader market volatility.

Over the past year, Regeneron's stock has reached a high of $800.99 and a low of $476.49. This range demonstrates the stock's potential for growth and the challenges it has faced. As the market anticipates reduced volatility during the shortened holiday week, Regeneron's stock may continue to attract attention from investors seeking stability and growth opportunities.